InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

Closed (no longer recruiting)Last updated: 16 January 2024

SOLACE 2: This Phase II trial is comparing the effectiveness of a chemotherapy drug (Olaparib) alone and as part of a combination therapy in patients with recurrent ovarian, fallopian tube or primary peritoneal cancers that have homologous recombination repair defectsA Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects

Clinical summary


Participants will be randomised to receive treatment according to one of the following three groups: (1) Olaparib and cyclophosphamide (50mg daily) followed by olaparib and durvalumab (1500mg every 4 weeks for 12 cycles), or (2) Olaparib followed by olaparib and durvalumab (as above), or (3) Olaparib alone. In each group, 300mg Olaparib will be administered orally, twice daily until progression occurs.


This trial is treating patients with Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer


Female Reproductive System Cancers Gynaecological





Trial Acronym


More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

University of Sydney

Scientific Title

A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects



1. Women, aged 18 years and older, with histologically confirmed high-grade serous carcinoma of the ovary, fallopian tube or primary peritoneum.
2. Undergone prior adequate debulking surgery, as appropriate, and 1 line of platinum-based chemotherapy. Patients who received bevacizumab or hormonal therapy as part of first-line treatment are eligible.
3. Known germline BRCA1 and BRCA2 status. Both BRCA mutant and BRCA wild-type patients are eligible, but they must have normalisation of CA125 to less than upper limit of normal (ULN), defined as 35 units/mL, by the end of first-line chemotherapy.
4. CA125 progression after first-line treatment, occurring 6 months or more following the last dose of chemotherapy. Participants must have raised CA125 readings twice the ULN (greater than or equal to 70 kU/L) on 2 occasions at least 1 week apart. The following circumstances are also considered eligible:
• If CA125 is less than 70 kU/L, patient must have evaluable disease on imaging (RECIST measurable or non-measurable);
• In the absence of RECIST measurable disease, CA125 progression (greater than or equal to 70 kU/L) after first-line treatment occurring 4 months or more following last dose of chemotherapy is allowed.
5. No indication for immediate chemotherapy or secondary debulking surgery.
6. ECOG performance status of 0-1.
7. Confirmation of the availability of tumour tissue (FFPE) for translational studies (a cell pellet from ascites or pleural fluid is not acceptable). If no tissue is available, patients will not be eligible for this study.
8. Adequate bone marrow function (measured within 28 days prior to registration and with values within the ranges specified below):
• Absolute neutrophil count equal to or greater than 1.5 x 109 /L
• Platelet count equal to or greater than 100 x 109 /L
• Haemoglobin equal to or greater than 100 g/L with no blood transfusion in the past 28 days
• Peripheral blood smear must not show any features suggestive of myelodysplastic syndrome/acute myeloblastic leukaemia.
9. Adequate liver function, as follows:
• Total bilirubin equal to or less than 1.5 x institutional upper limit of normal (ULN)
• Alkaline phosphatase (ALP), equal to or less than 2.5 x ULN (or equal to or less than 5 x ULN if liver metastases AST (SGOT), ALT (SGPT are present)
10. Adequate renal function, as follows:
• Serum creatinine equal to or less than 1.5 x ULN, or
• Creatinine clearance greater than 50mL/min (Cockcroft-Gault Formula)
11. Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments.
12. Signed, written informed consent prior to any study specific procedures.


1. Previous randomisation in the present study.
2. Any previous treatment with a PARP inhibitor, including olaparib.
3. Any previous treatment with durvalumab, or any other anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibodies or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways.
4. Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.
5. Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John’s Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks from the last study dose for other agents.).
6. Treatment with any investigational product during the last 14 days (or a longer period depending on the defined characteristics of the agents used).
7. Patients receiving any systemic anti-cancer treatment (including endocrine therapy, chemotherapy or VEGF-targeted agents) or radiotherapy (except for palliative reasons), within 14 days from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used).
8. Patients who are unable to swallow orally administered medication or have gastrointestinal disorders likely to interfere with absorption of the study medication (e.g. including but not limited to partial bowel obstruction or chronic malabsorption syndrome, Crohn’s disease and ulcerative colitis).
9. Suspected brain or leptomeningeal metastases, untreated brain metastases or current clinical or radiological progression of known brain metastases, or requirement for steroid therapy for brain metastases. Patients with treated brain metastases are eligible if they have been stable and off steroids for equal to or greater than 3 weeks.
10. Patients with known haemorrhagic cystitis.
11. No history of other active malignancy.
12. History of known or suspected auto-immune disease other than vitiligo, type 1 diabetes, residual hypothyroidism due to an autoimmune condition requiring only hormone replacement, or psoriasis not requiring systematic treatment within the last 2 years.
13. Prior allogeneic organ transplant, double umbilical cord blood transplantation, inflammatory bowel disease (e.g. Crohn’s disease, ulcerative colitis), pneumonitis, tuberculosis, or primary immunodeficiency.
14. Patients with prior diagnosis of myelodysplastic syndrome or acute myeloid leukaemia. Any abnormal blood films at baseline need to be reviewed to exclude these conditions.
15. Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid. In the case of short term use of systemic corticosteroids (less than 24 hours within 28 days) of greater than 10 mg/day of prednisone or an equivalent corticosteroid, the required washout period prior to starting the first dose of durvalumab is 7 days.
16. Receipt of live attenuated vaccination within 30 days before the first dose of durvalumab.
17. Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable outside of 28 days prior to registration).
18. Patients with documented serologically positive hepatitis B or C (defined as positive result for hepatitis B core antibody or hepatitis C antibody).
19. Patients who are known to be serologically positive for human immunodeficiency virus (HIV).
20. Within 28 days of registration, patients must have two ECG assessments within a 24 hour period. Patients must not have a resting ECG with a QTc interval of >470 msec or a family history of long QT syndrome.
21. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable angina pectoris, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan, active peptic ulcer disease or gastritis, active bleeding diathesis, or any psychiatric disorder/social situation that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent.
22. Major surgical procedure within 14 days prior to study treatment, or still recovering from any effects of major surgery.
23. Any unresolved toxicity NCI CTCAE Grade >1 from previous anticancer therapy. Subjects with Grade equal to or less than 2 neuropathy or Grade equal to or less than 2 alopecia are exceptions to this criterion.
24. Patients with known hypersensitivity to cyclophosphamide or any excipients of olaparib, cyclophosphamide or durvalumab.
25. Life expectancy of less than 12 months.
26. Pregnancy, lactation, or inadequate contraception. Most patients would have undergone prior oophorectomy and hysterectomy as part of surgical treatment for ovarian cancer. For women who have ovaries and uterus in situ, they must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration.


  • You have had treatment, but your cancer has come back.


  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Closed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.


Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.